Today, ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company reported financial results for the quarter ended 30 June 2019 and provided an update on its clinical activities.
For more information, please refer to the English and Chinese press release.